Oncorus, Inc., an oncolytic virus therapeutics company focused on driving innovation to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Ted Ashburn, M.D., Ph.D., will provide a company overview and pipeline update at the following upcoming healthcare investor conferences in New York City:
About Oncorus
At Oncorus, we are driving innovation to deliver next-generation, best-in-class oncolytic virus therapies to transform outcomes for cancer patients.We are advancing a portfolio of locally and systemically administered oncolytic virus therapies for a broad spectrum of indications with significant unmet needs based on our oncolytic herpes simplex virus and synthetic oncolytic virus platforms. Our team has engineered proprietary, multidimensional innovations into both platforms to enable us to deliver on the full potential of oncolytic virus therapies to dramatically improve outcomes for cancer patients. Please visit www.oncorus.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005307/en/
Media Contact:
Liz Melone
liz@scientpr.com
617-256-6622